Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on CN116589426B. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel iridium catalyzed asymmetric synthesis offers high enantioselectivity. Reduces costs and improves supply chain reliability for pharmaceutical intermediates globally.
Patent CN116589426B details a novel iridium-catalyzed asymmetric [4+2]-cycloaddition for high-purity chiral 1,3-benzoxazine intermediates, offering mild conditions and supply chain reliability.
Novel iridium-catalyzed asymmetric method offers high selectivity and mild conditions for pharmaceutical intermediate manufacturing supply chain optimization and cost efficiency.